Skip to content

Effects Of Optimized Blinking Training on Visual Function and Tear Film Parameters in Individuals With CVS

Effects Of Optimized Blinking Training on Visual Function and Tear Film Parameters in Individuals With Computer Vision Syndrome

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06913816
Enrollment
52
Registered
2025-04-06
Start date
2025-03-20
Completion date
2026-02-20
Last updated
2025-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Computer Vision Syndrome

Brief summary

Computer vision syndrome (CVS), refers to a range of eye and vision issues caused by extended use of computers, tablets, e-readers, and smartphones. Computer users experience visual symptoms, such as eyestrain, headaches, eye discomfort, dry eyes, double vision, and blurred vision, especially after long periods of looking at screens, whether up close or at a distance.

Detailed description

Individuals will be randomly assigned to either an experimental group (group A) receiving OBT with routine rehabilitation CVS management 20-20-20 rule, blue light-blocking glasses, and polyvinyl alcohol eye drops or a control group (group B) receiving only routine rehabilitation, including the 20-20-20 rule, blue light-blocking glasses, and polyvinyl alcohol eye drops. OBT consisted of structured blinking exercises performed thrice daily for three months. Objective outcomes, including tear film parameters and visual function using subjective Computer Vision Syndrome Questionnaire (CVS-Q) shall be evaluated. The collected data will be analysed by using SPSS.

Interventions

DIAGNOSTIC_TESTGrouyp 1 (without blinking exercises).

Group B (Control Group) The control group will continue receiving only the routine rehabilitation (without blinking exercises). Routine rehabilitation included the 20-20-20 rule, blue light-blocking glasses, and polyvinyl alcohol eye drops.

COMBINATION_PRODUCTEXP group (Routine CVS treatment)

Group A (Experimental Group): Individuals in the Experimental group will receive Routine CVS treatment with optimized blinking exercise. Routine rehabilitation includes the 20-20-20 rule, blue light-blocking glasses, and polyvinyl eye drops. The blinking exercise involved the individuals looking at an object 6 meters away for 5 seconds, followed by complete eyelid closure for 5 seconds. This cycle was repeated for 5 minutes, twice a day.

Sponsors

Superior University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Individuals aged 18-40 years who work on computers or digital devices for at least 3 to 6 hours daily. * Both Male and Female. * Individuals who could undergo a complete ocular examination. * Presence of symptoms consistent with digital eye strain. * Presented with eye complaints such as eye fatigue, burning, irritation, redness, and blurred vision due to long-term computer or digital screen use. * Symptoms worsened during exposure to digital screen light.

Exclusion criteria

* Use of medications that might influence tear production or ocular surface status (e.g., antihistamines, antidepressants). * Diagnosed neurological or systemic conditions that impact vision or blink patterns (e.g., Parkinson's disease, multiple sclerosis). * Individual's with a history of ocular surface diseases such as conjunctivitis or keratitis. * History of any psychiatric diagnosis.

Design outcomes

Primary

MeasureTime frameDescription
Computer Vision Syndrome (CVS-Q)12 MonthsThe Computer Vision Syndrome Questionnaire (CVS-Q) assesses the frequency and intensity of 16 ocular and visual symptoms related to prolonged screen use, with a total score of 6 or more indicating CVS If the total score is ≥6 points, the individual is considered to suffer Computer Vision Syndrome

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026